Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Cellectricon and Censo ally to provide human iPSC-based discovery services

Cellectricon and Censo ally to provide human iPSC-based discovery services

9th September 2016

Cellectricon has announced a new collaboration with UK-based stem cell technology company Censo Biotechnologies.

The agreement will see the partners ally to provide a suite of high-quality human induced pluripotent stem cells (iPSC)-based discovery services to support preclinical neuroscience and chronic pain research.

Censo will be able to provide key stem cell knowledge to enhance Cellectricon's proprietary discovery services, thereby helping the companies met growing industry demands for drug discovery models that are closer and more relevant to humans.

David Burns, chief executive officer at Cellectricon, said: "Censo's extensive stem cell knowledge complements our current expertise and screening service offering in the field of neuroscience."

Censo Biotechnologies provides human cells and contract research services for drug discovery, toxicity testing and cell banking. The company was established earlier this year through the merger of Roslin Cellab and Roslin Cell Sciences and operates facilities in both Edinburgh and Cambridge.

Cellectricon, meanwhile, is an established provider of advanced cell-based discovery screening services.

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801825015-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.